Wave Life Sciences Ltd. (NASDAQ: WVE) is a Healthcare company (Biotechnology) with a market capitalization of $560M. The Maz Rating grades it against the other companies in its sector.
Wave Life Sciences Ltd.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.84, Wave Life Sciences Ltd. trades at 7.9x sales and 1.4x book value. Over the last twelve months it generated about $71M of revenue and a net loss of $210M. It runs a gross margin of 96.8%, an operating margin of -320.9% and a net margin of -296.9%. It shows return on equity of -44.5%, return on invested capital of -49.7% and a free cash flow yield of -36.0%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 8.38. Over the past 52 weeks the share price ranged from $2.77 to $21.73, with a beta of -1.44.
Wave Life Sciences Ltd. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 1 Strong Buy, 22 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Wave Life Sciences Ltd. (WVE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 53.2% / 30% · Interest income / Revenue 33.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 53.2% / 33% · Receivables / Mkt Cap (36m) 1.48% / 49% · Interest income / Revenue 33.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 53.2% / 33.33% · Receivables / Mkt Cap (24m) 1.48% / 33.33% · Interest income / Revenue 33.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.4% / 33.33% · Receivables / Avg Assets (4Q) 0.62% / 33.33% · Interest income / Revenue 33.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 84.8% / 33.33% · (Cash+Recv) / Total Assets 87.2% / 33.33% · Interest income / Revenue 33.3% / 5% | Fail |
No. As of September 2026, Wave Life Sciences Ltd. (WVE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Wave Life Sciences Ltd. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 33.3% of each dividend: Wave Life Sciences Ltd.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.